An observational study in Financial Toxicity and Cancer Patients, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Ankara Etlik City Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This cross-sectional observational study evaluates the associations between patient-reported financial toxicity, health-related quality of life (HRQoL), and informal caregiver burden among hospitalized adult patients with solid tumors. Additionally, the study characterizes material hardship, basic-needs insecurity, cost-related healthcare disruptions, and unmet needs for financial navigation within an inpatient oncology setting. Hospitalized patients complete validated Turkish versions of the Comprehensive Score for Financial Toxicity (COST-FACIT Version 2), the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), the Hospital Anxiety and Depression Scale (HADS), the 14-item Health Literacy Scale (HLS-14), and structured items assessing socioeconomic hardship and care disruptions. Linked informal caregivers complete the 22-item Zarit Burden Interview (ZBI-22). Findings aim to inform structured financial screening, referral pathways, and supportive oncology care for hospitalized patients and their caregivers.
Cancer-related financial hardship extends beyond direct medical costs to income loss, out-of-pocket expenses, difficulty meeting basic household needs, and strain on informal caregivers. This single-center, cross-sectional observational study was conducted at the Department of Medical Oncology, Ankara Etlik City Hospital (Ankara, Türkiye) between January 2025 and June 2026 to comprehensively characterize financial vulnerability across patient, caregiver, and healthcare delivery domains.
The study enrolled hospitalized adults aged 18 years or older with a histologically confirmed solid malignancy (stages I to IV) admitted for planned or unplanned inpatient oncology care, alongside their linked informal caregivers. All participating patients and informal caregivers provided written informed consent prior to survey administration.
Participating patients completed a comprehensive battery of validated Turkish assessment instruments and structured questionnaires:Comprehensive Score for Financial Toxicity (COST-FACIT, Version 2): An 11-item instrument rated on a 5-point Likert scale assessing subjective financial well-being over the preceding 7 days (total score range: 0-44, with higher scores indicating better financial well-being and lower financial toxicity). EORTC QLQ-C30: A 30-item questionnaire evaluating global health status/quality of life (primary outcome), five functional domains (physical, role, emotional, cognitive, and social functioning), and symptom scales (transformed linearly to a 0-100 scale). Hospital Anxiety and Depression Scale (HADS): A 14-item instrument with two 7-item subscales evaluating anxiety and depression symptoms (each ranging from 0 to 21, with higher scores denoting greater emotional distress). Health Literacy Scale (HLS-14): A 14-item scale evaluating functional, communicative, and critical health literacy domains. Material Hardship, Care Disruptions, and Financial Navigation Assessment: Structured items assessing experiences over the preceding 3 months, including household income decline, employment disruptions, out-of-pocket medical expenditures relative to household income, financial coping strategies, basic-needs insecurity, cost-related care disruptions (prescription medication nonadherence, missed oncology appointments, and delayed anticancer treatment attributable to cost), perceived need for financial navigation, referral offering, and referral acceptance. Linked informal caregivers completed the validated Turkish version of the 22-item Zarit Burden Interview (ZBI-22), rated on a 5-point Likert scale (total score range: 0-88, with higher scores indicating greater caregiver burden), along with items regarding caregiving hours and caregiver financial strain. Statistical analyses utilized multivariable ordinary least squares regression with HC3 heteroskedasticity-robust standard errors for continuous quality-of-life, psychological distress, and caregiver burden outcomes, and modified Poisson regression with robust variance estimation to estimate adjusted prevalence ratios (aPRs) for binary hardship, care disruption, and unmet navigation outcomes. Missing-data sensitivity analyses were performed using multiple imputation and inverse probability weighting.
100 studies on the registry are indexed under Financial Stress; 34 are open to participants now.
This study's enrollment of 896 is above the median of 283 across 37 observational studies indexed under Financial Stress.
Browse Financial Stress studies →Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Adults aged 18 years or older with a histologically confirmed solid malignancy (stages I to IV) hospitalized for planned or unplanned care at the Department of Medical Oncology, Ankara Etlik City Hospital, along with their linked informal caregivers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For linked informal caregiver assessments, separate written informed consent is obtained from participating caregivers.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged ≥18 years with histologically confirmed stage I-IV solid malignancies hospitalized for planned or unplanned care in the medical oncology ward (n = 896), along with their linked informal caregivers (n = 707). Patients completed the COST-FACIT Version 2, EORTC QLQ-C30, HADS, HLS-14, and structured questionnaires on material hardship, cost-related care disruptions, and financial navigation needs. Linked informal caregivers completed the 22-item Zarit Burden Interview (ZBI-22). No clinical or pharmaceutical intervention was administered.
Other: Administration of validated psychosocial, financial toxicity, and caregiver burden questionnaires
Single time-point cross-sectional administration of validated Turkish questionnaires (COST-FACIT v2, EORTC QLQ-C30, HADS, HLS-14, ZBI-22) and structured socioeconomic/navigation survey items during index hospitalization.
Also known as: Psychosocial assessment tools, Self-reported questionnaires
Global Health-Related Quality of Life (EORTC QLQ-C30 Global Health Status Score)
Global health-related quality of life is assessed using the two-item global health status/quality-of-life scale of the validated Turkish version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores are linearly transformed to a scale ranging from 0 to 100, with higher scores indicating better global health status and quality of life.
Time frame: At index hospitalization enrollment (single time-point assessment)
Informal Caregiver Burden (Zarit Burden Interview [ZBI-22])
Caregiver burden among linked informal caregivers is assessed using the validated Turkish version of the 22-item Zarit Burden Interview (ZBI-22), rated on a 5-point Likert scale (total score range: 0 to 88, with higher scores indicating greater caregiver burden). Multivariable linear regression evaluates the adjusted association per 5-point higher patient COST-FACIT score with ZBI-22 scores.
Time frame: At index hospitalization enrollment (single time-point assessment)
Anxiety Symptoms (HADS Anxiety Subscale)
Anxiety symptoms are assessed using the seven-item anxiety subscale of the validated Turkish version of the Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.
Time frame: At index hospitalization enrollment (single time-point assessment).
Prevalence of Cost-Related Healthcare Disruptions
Proportion of patients reporting any cost-related healthcare disruption over the preceding 3 months, defined as a composite and individual components of prescription medication nonadherence, missed oncology appointments, or delayed anticancer treatment attributable to cost, and its adjusted prevalence ratio (aPR) per 5-point higher COST-FACIT score.
Time frame: At index hospitalization enrollment (assessing the preceding 3 months)
Material Hardship and Basic-Needs Insecurity
Proportion of patients reporting basic-needs insecurity, household income decline, out-of-pocket medical expenditures exceeding 10% of 3-month household income, and utilization of financial coping strategies over the preceding 3 months.
Time frame: At index hospitalization enrollment (assessing the preceding 3 months)
Unmet Financial Navigation Needs, Referral Offering, and Referral Acceptance
Proportion of hospitalized patients reporting a need for financial navigation assistance, proportion of patients with reported need who had not been offered a referral (unmet referral opportunity), and referral acceptance rate among those offered a referral.
Time frame: At index hospitalization enrollment (single time-point assessment)
Depressive Symptoms (HADS Depression Subscale)
Depressive symptoms are assessed using the seven-item depression subscale of the validated Turkish version of the Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21, with higher scores indicating more severe depressive symptoms.
Time frame: At index hospitalization enrollment (single time-point assessment).
Plan to share: No — Individual participant data (IPD) will not be shared due to institutional policies and ethical considerations regarding patient confidentiality and data protection. Data use is restricted to the research team listed in the study protocol, and no external data sharing is planned at this stage.
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Jun 2026, 17 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2025 → Jan 2025, primary completion Oct 2025 → Jun 2026 and completion Feb 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.